Content about Cetuximab

February 8, 2013
Reports: Amgen plans six biosimilars

Biotech drug maker Amgen plans to launch six biosimilar drugs starting in 2017, according to published reports.

NEW YORK — Biotech drug maker Amgen plans to launch six biosimilar drugs starting in 2017, according to published reports.

January 25, 2013
New indication approved for Genentech drug

The Food and Drug Administration has approved a new use for a cancer drug made by Roche unit Genentech, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new use for a cancer drug made by Roche unit Genentech, the agency said.

The FDA announced the approval of Avastin (bevacizumab) combined with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin chemotherapy for treating colorectal cancer that has spread to other parts of the body, also known as metastatic colorectal cancer, or mCRC.

The drug is also approved for treating lung cancer, kidney cancer and brain cancer.

July 9, 2012
FDA approves Lilly, BMS drug for KRAS wild-type colorectal cancer

The Food and Drug Administration has approved a drug made by Eli Lilly and Bristol-Myers Squibb for treating a form of colorectal cancer, the two companies said.

NEW YORK — The Food and Drug Administration has approved a drug made by Eli Lilly and Bristol-Myers Squibb for treating a form of colorectal cancer, the two companies said.

Lilly and Bristol announced the approval of Erbitux (cetuximab) for treating colorectal cancer that is KRAS mutation-negative, expresses the epidermal growth factor receptor and has spread to other parts of the body, also known as metastasis. The drug is approved for use alongside a chemotherapy combination containing irinotecan, 5-fluorouracil and leucovorin, also known as FOLFIRI.

November 7, 2011
FDA gives new approval to Bristol-Myers Squibb's, Lilly's Erbitux

The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb for treating head and neck cancer, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb and Eli Lilly & Co. for treating head and neck cancer, the agency said Monday.

The FDA announced the approval of Erbitux (cetuximab) for use with chemotherapy in treating head and neck cancer that had spread to other parts of the body. The drug originally was approved in 2004 for treating certain cases of late-stage colon cancer in patients who had stopped responding to chemotherapy.

October 5, 2010
Amgen: Vectibix improves progression-free survival for cancer patients

An investigative biotech drug administered together with chemotherapy helped extend the lives of cancer patients...

THOUSAND OAKS, Calif. An investigative biotech drug administered together with chemotherapy helped extend the lives of cancer patients without their disease getting worse, also known as progression-free survival, according to results of two clinical trials announced this week by Amgen.

 

August 11, 2010
Amgen's Vectibix fails to meet main goal in trial

An investigational biotech drug didn’t significantly improve patients’ survival, according to results of a late-stage...

June 6, 2010
Bristol-Myers Squibb: Skin cancer drug increased patient survival in clinical trial

An investigational drug for skin cancer that had spread to other parts of the body...

May 20, 2010
Boehringer Ingelheim's cancer drug may be 'next generation' treatment

Data from a late-stage clinical trial of an investigational drug by Boehringer Ingelheim could show...

May 16, 2010
Lilly to present more than 50 studies at oncology conference

The cancer drug arm of Eli Lilly plans to show data from more than 50...